MX2018009405A - Sintesis y composicion de bibliotecas de rapafucina. - Google Patents

Sintesis y composicion de bibliotecas de rapafucina.

Info

Publication number
MX2018009405A
MX2018009405A MX2018009405A MX2018009405A MX2018009405A MX 2018009405 A MX2018009405 A MX 2018009405A MX 2018009405 A MX2018009405 A MX 2018009405A MX 2018009405 A MX2018009405 A MX 2018009405A MX 2018009405 A MX2018009405 A MX 2018009405A
Authority
MX
Mexico
Prior art keywords
synthesis
rapafucin
libraries
composition
compounds
Prior art date
Application number
MX2018009405A
Other languages
English (en)
Inventor
Liu Jun
Wang Jingxin
Guo Zufeng
hong Sam
Liu Wukun
Peng Hanjing
Das Manisha
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2018009405A publication Critical patent/MX2018009405A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan una biblioteca de rapafucina que contiene compuestos de la estructura general (ve formula) Y una síntesis de estos compuestos.
MX2018009405A 2016-02-04 2017-02-03 Sintesis y composicion de bibliotecas de rapafucina. MX2018009405A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291437P 2016-02-04 2016-02-04
PCT/US2017/016481 WO2017136708A1 (en) 2016-02-04 2017-02-03 Synthesis and composition of rapafucin libraries

Publications (1)

Publication Number Publication Date
MX2018009405A true MX2018009405A (es) 2018-11-09

Family

ID=59501078

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009405A MX2018009405A (es) 2016-02-04 2017-02-03 Sintesis y composicion de bibliotecas de rapafucina.

Country Status (8)

Country Link
US (1) US10662220B2 (es)
EP (1) EP3411413A4 (es)
JP (2) JP6891183B2 (es)
CN (1) CN108713028B (es)
AU (1) AU2017214550B2 (es)
CA (1) CA3013589A1 (es)
MX (1) MX2018009405A (es)
WO (1) WO2017136708A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI640541B (zh) 2011-12-28 2018-11-11 中外製藥股份有限公司 Peptide compound having an annular portion and pharmaceutical composition thereof
US11708391B2 (en) * 2016-02-04 2023-07-25 The Johns Hopkins University Rapaglutins, novel inhibitors of GLUT and use thereof
CN108713028B (zh) * 2016-02-04 2021-12-28 约翰霍普金斯大学 rapafucin文库的合成和组合物
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
CN108697701B (zh) * 2016-02-04 2021-10-26 约翰霍普金斯大学 平衡型核苷转运蛋白1的抑制剂Rapadocin及其用途
WO2018225864A1 (ja) * 2017-06-09 2018-12-13 中外製薬株式会社 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ
TW202126323A (zh) 2019-10-01 2021-07-16 約翰斯赫普金斯大學 雷帕弗辛（Ｒａｐａｆｕｃｉｎ）衍生化合物及其使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
CN1187127A (zh) * 1995-06-07 1998-07-08 吉尔福特药品有限公司 旋转异构酶活性抑制剂
US7056935B2 (en) 1995-06-07 2006-06-06 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
EP1053241A1 (en) * 1998-02-13 2000-11-22 President And Fellows Of Harvard College Novel dimerizing agents, their production and use
US6984635B1 (en) * 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
US20080306098A1 (en) * 2006-11-06 2008-12-11 Mutz Mitchell W Pharmacokinetics of protease inhibitors and other drugs
WO2010004304A1 (en) * 2008-06-17 2010-01-14 Biotica Technology Limited Novel compounds and methods for their production
WO2012075048A2 (en) 2010-11-30 2012-06-07 The Johns Hopkins University Hybrid cyclic libraries and screens thereof
EP2607352A1 (en) 2011-12-22 2013-06-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pipecolate-diketoamides for treatment of psychiatric disorders
EP3007696B1 (en) * 2013-06-14 2019-10-16 The Board of Regents of The University of Texas System Novel allosteric inhibitors of proteasome and methods of use thereof
CN108713028B (zh) 2016-02-04 2021-12-28 约翰霍普金斯大学 rapafucin文库的合成和组合物

Also Published As

Publication number Publication date
AU2017214550B2 (en) 2024-03-07
AU2017214550A1 (en) 2018-08-16
WO2017136708A1 (en) 2017-08-10
US20190092808A1 (en) 2019-03-28
JP6891183B2 (ja) 2021-06-18
JP2021138726A (ja) 2021-09-16
EP3411413A4 (en) 2019-09-18
CN108713028B (zh) 2021-12-28
EP3411413A1 (en) 2018-12-12
CA3013589A1 (en) 2017-08-10
JP7158532B2 (ja) 2022-10-21
JP2019510738A (ja) 2019-04-18
CN108713028A (zh) 2018-10-26
US10662220B2 (en) 2020-05-26

Similar Documents

Publication Publication Date Title
MX2018009405A (es) Sintesis y composicion de bibliotecas de rapafucina.
EP3642182A4 (en) COMPOUNDS, COMPOSITIONS AND SYNTHESIS METHODS
MX2018006148A (es) Inhibidores de cxcr2.
PH12017502255A1 (en) Nrf2 regulators
MX2018001430A (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
MX2019005076A (es) Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2.
TW201613911A (en) Heterocyclic compounds and uses thereof
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
EP3597723A4 (en) MIXTURE CONTAINING PEROVSKITE COMPOUND
MX2017007629A (es) Compuestos inhibidores de bcl-xl que tienen una baja permeabilidad en las celulas y conjugados de anticuerpo-farmaco que los incluyen.
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
MX2018002217A (es) Nuevos compuestos biciclicos como inhibidores de autotaxina (atx).
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
EP3768418A4 (en) SYNTHESIS OF AMMONIA USING ELECTRONS PRODUCED BY PLASMA
ZA202006165B (en) Hydrogen carrier compounds
ZA202102492B (en) Compounds containing deuterium
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
DK3648743T3 (da) Pressede tabletter, der omfatter nitrooxyforbindelser
PL3630752T3 (pl) Podstawione związki zawierające azot
SG11202006252YA (en) Hyper-branched compounds, synthesis and uses thereof
EP3790385A4 (en) STABILIZED CHEMICAL COMPOSITION
MX2019012665A (es) Compuestos organicos.
EP3616692A4 (en) PHARMACEUTICAL COMPOSITION WITH NM23 ACTIVATOR FOR INHIBITION OF CANCER METASTASIS
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.